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Prion strains associated with iatrogenic 
CJD in French and UK human growth hormone 
recipients
Jean‑Yves Douet1†, Alvina Huor1†, Hervé Cassard1, Séverine Lugan1, Naïma Aron1, Chloé Mesic1, Didier Vilette1, 
Tomás Barrio1, Nathalie Streichenberger2,3, Armand Perret‑Liaudet2,3, Marie‑Bernadette Delisle4, Patrice Péran4, 
Jean‑Philippe Deslys5, Emmanuel Comoy5, Jean‑Luc Vilotte6, Katayoun Goudarzi6, Vincent Béringue7, 
Marcelo A. Barria8, Diane L. Ritchie8, James W. Ironside8 and Olivier Andréoletti1* 
Abstract 
Treatment with human pituitary‑derived growth hormone (hGH) was responsible for a significant proportion of iatro‑
genic Creutzfeldt–Jakob disease (iCJD) cases. France and the UK experienced the largest case numbers of hGH‑iCJD, 
with 122 and 81 cases respectively. Differences in the frequency of the three PRNP codon 129 polymorphisms (MM, 
MV and VV) and the estimated incubation periods associated with each of these genotypes in the French and the 
UK hGH‑iCJD cohorts led to the suggestion that the prion strains responsible for these two hGH‑iCJD cohorts were 
different. In this study, we characterized the prion strains responsible for hGH‑iCJD cases originating from UK (n = 11) 
and France (n = 11) using human PrP expressing mouse models. The cases included PRNP MM, MV and VV genotypes 
from both countries. UK and French sporadic CJD (sCJD) cases were included as controls. The prion strains identified 
following inoculation with hGH‑iCJD homogenates corresponded to the two most frequently observed sCJD prion 
strains  (M1CJD and  V2CJD). However, in clear contradiction to the initial hypothesis, the prion strains that were identified 
in the UK and the French hGH‑iCJD cases were not radically different. In the vast majority of the cases originating from 
both countries, the  V2CJD strain or a mixture of  M1CJD +  V2CJD strains were identified. These data strongly support the 
contention that the differences in the epidemiological and genetic profiles observed in the UK and France hGH‑iCJD 
cohorts cannot be attributed only to the transmission of different prion strains.
Keywords: Prion disease, Iatrogenic CJD, Growth hormone
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
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Introduction
Prion diseases (otherwise known as transmissible spongi-
form encephalopathies) are a group of transmissible neu-
rodegenerative disorders that occur naturally in man and 
a range of other mammalian species, including scrapie 
in sheep and goats, and chronic wasting disease in deer 
and elk. Prion diseases are characterized by the accumu-
lation of a misfolded form of the normal cellular prion 
protein  (PrPC) in the central nervous system (CNS) [1]. 
This misfolded protein (commonly referred to as  PrPSc) 
is considered to be the major, if not the only, component 
of the transmissible agents or prions that are responsible 
for these diseases [2]. Serial passage of sheep scrapie in 
mice by intracerebral inoculation identified the presence 
of distinct strains of the transmissible agent based on the 
individual biological properties in the mice that become 
stable on serial passage [3]. These properties include the 
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disease incubation period and neuropathological pheno-
type, particularly the distribution and severity of spongi-
form change in the brain. In the apparent absence of 
any nucleic acid associated with the transmissible agent, 
these variations in strain properties have been accounted 
for by conformational variability in  PrPSc that is self-
propagating [2].
Human prion diseases occur in sporadic, genetic and 
acquired forms. The commonest of these is the sporadic 
form of Creutzfeldt–Jakob disease (sCJD), which has a 
worldwide distribution at a remarkably consistent inci-
dence of 1–2 cases per million population per annum. 
The acquired forms of human prion disease include kuru, 
iatrogenic Creutzfeldt–Jakob disease (iCJD) and variant 
Creutzfeldt–Jakob disease (vCJD) [4].
The clinicopathological phenotype of human prion 
diseases is variable, particularly in sCJD. One major 
determinant of this variability is the naturally occurring 
polymorphism at codon 129 in the human prion protein 
gene (PRNP), which can encode either methionine (M) 
or valine (V), resulting in three possible genotypes: MM, 
MV and VV. The second major determinant is the iso-
form of the protease-resistant core of  PrPSc (referred to 
as  PrPres) which may be detected by Western blot analysis 
in brain tissue from affected patients.  PrPres occurs as two 
major isoforms in sCJD cases that differ in the molecu-
lar weight of the unglycosylated fragments, designated 
Type 1 (21 kDa) and Type 2 (19 kDa). Distinct subtypes 
of sCJD have been recognized according to their clinical 
and neuropathological features, which largely correspond 
to the six possible codon 129 genotype/PrPres type com-
binations (MM1, MV1, VV1, MM2, MV2 and VV2) [5]. 
However, both type 1 and type 2  PrPres can be detected 
within either the same or different brain areas in up to 
35% of sCJD patients [6, 7]. It has been proposed that 
the different sCJD subtypes could result from the prop-
agation of different strains of sCJD prions in patients. 
Experimental transmissions of sCJD brain homogenates 
to transgenic mice have demonstrated the existence of at 
least five strains of sCJD prions [8–13].
Although the precise relationship between prion strain 
diversity and the clinicopathological subtypes of sCJD 
remains imperfectly characterized, two strains named 
 M1CJD and  V2CJD seem to account for the most frequent 
forms of sCJD;  M1CJD is predominantly found in the 
brain of MM/MV1 sCJD patients, while the  V2CJD strain 
is generally found in VV/MV2 sCJD patients [8, 9, 11, 
14]. However, in up to 35% of sCJD patients the co-exist-
ence of both  M1CJD and  V2CJD strains was demonstrated 
by bioassay [11].
The first reported case of iatrogenic CJD (iCJD), 
occurring in a recipient of a corneal graft from a donor 
who had died from sCJD, was published in 1974 [15]. 
Since then, cases of iCJD have also been identified in 
small numbers of patients on whom neurosurgical 
instruments or intracerebral electrodes previously used 
on the brains of patients with CJD were subsequently 
used [16]. Larger numbers of iCJD cases (over 200 in 
each group) have occurred in patients inoculated with 
human pituitary-derived growth hormone (hGH), 
and in patients who received an implant of lyophilised 
human dura mater (hDM) during neurosurgery. Treat-
ment of primary or secondary growth hormone defi-
ciency in children with hGH was commenced initially 
in the 1950s on a small scale in a few countries. The 
subsequent clinical success of this treatment resulted 
its use on a much larger scale and in more countries. 
The first case of iCJD in a patient treated with hGH was 
reported in 1985, since when the use of hGH has ceased 
in many countries and replacement therapy with bio-
synthetic growth hormone was instigated [16].
The incidence of hGH-iCJD varies from country to 
country and appears to be related to the scale of the 
local hGH production process and the likelihood of 
prion contamination in the selection of autopsy cases 
for pituitary collection, e.g. the collection of pituitary 
glands from elderly patients. Since 1985, over 240 cases 
of iCJD in hGH recipients have been reported in several 
countries, with the largest numbers of cases occurring 
in France and the United Kingdom (UK). Four cases of 
iCJD in human pituitary gonadotrophin recipients have 
also occurred, all in Australia; one of these patients 
died in the UK [16].
Overall, 1849 patients from the UK and Ireland were 
treated with hGH produced in the UK from 1959 until 
1985. Since 1985, 81 deaths from iCJD have occurred 
in this cohort. It has been established that one particu-
lar preparation of UK pituitary-derived hGH (the Har-
tree-modified Wilhelmi (HWP) preparation) had been 
administered to all hGH recipients who had developed 
iCJD, albeit from different batches, in varying quantities 
and over different time periods [17]. In France, 122 cases 
of iCJD in 1443 hGH recipients have occurred between 
1991 and 2019. All were treated between December 1983 
and July 1985, which has been identified as a high- risk 
period for hGH-iCJD in France [18, 19].
Deaths from hGH-iCJD continue to occur in France 
and in the UK, with the most recent death occurring in 
2019 and 2020 respectively, 35 years since hGH therapy 
ceased in these countries. A precise calculation of incu-
bation periods in human pituitary hormone recipients is 
difficult, since the patients are often treated over a period 
of years; the time period from the mid-point of pituitary 
hormone treatment to the onset of clinical symptoms of 
iCJD is therefore used as an estimate for the incubation 
period.
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A major factor influencing incubation periods in hGH-
iCJD is the PRNP codon 129 polymorphism of the recipi-
ent. It has long been recognized that homozygosity at 
this locus may predispose to both iCJD and sporadic CJD 
(sCJD) [20]. In the healthy UK and French populations, 
the distribution of the individual genotypes at codon 129 
of the PRNP gene is similar at around 40% MM, 10% VV 
and 50% MV [16, 21].
Variations in the frequency of the three PRNP codon 
129 polymorphisms (MM, MV and VV) and estimated 
incubation periods associated with each of these three 
genotypes have been reported in hGH-iCJD cohorts in 
different countries [16].
In France, the mean incubation period for hGH-iCJD 
has been estimated at 14.2  years. However, incubation 
periods differed according to the patient’s age at start of 
treatment, with the shortest incubation periods observed 
in the group of patients aged between 10 and 13.7 years 
when treatment started. Incubation periods were also 
influenced by the patient’s PRNP codon 129 genotype, 
with mean values of 12.6 years in MM and VV homozy-
gotes and 17.6 years in MV heterozygotes [18].
The risk of developing iCJD in the UK hGH recipients 
was greatest in those patients who started treatment at 
ages 8–10 years [17]. Estimated incubation periods in the 
UK hGH-iCJD patients range from 7 to 40  years; these 
prolonged incubation periods are reminiscent of those 
occurring in kuru, where incubation periods of over 
40  years have been reported [22]. The incubation peri-
ods in the UK hGH-iCJD patients are also influenced by 
the patient’s PRNP codon 129 genotype, but in contrast 
to the French patients, UK VV homozygous patients had 
a mean incubation period of 14.3  years, while in MV 
heterozygous patients the mean incubation period was 
23.4 years. The longest incubation periods in UK patients 
occurred in codon 129 MM homozygotes (mean value 
30.8 years) [22].
These observations raised the hypothesis that different 
prion strains (most likely originating from undetected 
cases of sCJD in the donor population) contaminated 
the hGH preparations administered to recipients in the 
UK and in France, resulting in different incubation peri-
ods for each of the PRNP codon 129 subgroups between 
these countries [16, 23]. This study aims to test this 
hypothesis by performing experimental transmissions 
of 22 hGH-iCJD brain homogenates from patients with 
all three codon 129 genotypes from France (11 cases) 
and the UK (11 cases) into a panel of well characterized 
human-PrP-expressing transgenic mice (tgHu), following 
an established methodology that has been used exten-
sively to identify sCJD prion strains in a range of tissue 
samples from France, the UK and Spain [11, 14]. Sporadic 
CJD cases originating from France and the UK were also 
used as controls in this study. This is the first study, to 
our knowledge, where the strain characteristics of prions 
in hGH-iCJD cases have been defined and compared to 
sCJD prion strains.
In clear contradiction to the initial hypothesis, the 
prion strains that were identified in the UK and the 
French hGH-iCJD cases were not radically different. 
In the vast majority of the cases originating from both 
countries, the  V2CJD strain or a mixture of  M1CJD +  V2CJD 
strains were identified by the strain typing in tgHu. These 
data strongly support the contention that differences 
observed in the epidemiological profiles between hGH-
iCJD cases in the UK and France cannot be attributed 
solely to the transmission of different prion strains.
Materials and methods
Ethical statement
All animal experiments were performed in compliance 
with institutional and French national guidelines in 
accordance with the European Union Directives 86/609/
EEC and 2010/63/EU. Experiments were approved by 
the Committee on the Ethics of Animal Experiments of 
the author’s institutions: INRA Toulouse/ENVT (Permit 
Number: 01734.01).
Concerning the human CJD samples, in all cases 
informed consent for research was obtained and the 
material used had appropriate ethical approval for use in 
this project.
France: human brain samples were obtained from the 
Brain Bank of CHU of Toulouse, Cardiobiotec (Centre 
de Resources Biologiques des Hospices Civils de Lyon) 
and former French national reference laboratory (CEA, 
Fontenay aux roses) under approval number AC62009-
973/20-01-2010. Samples were pseudo-anonymized 
before dispatch.
UK: Human brain samples were obtained from the 
National CJD Research and Surveillance Unit Brain and 
Tissue Bank in Edinburgh, UK, which is part of the MRC 
Edinburgh Brain Bank. For the purposes of this study, 
samples were pseudo-anonymized using a Brain Bank 
reference number. All UK cases had informed consent 
for research and their supply and use in this study was 
covered by Ethics Approval (LREC 2000/4/157: National 
Creutzfeldt–Jakob disease tissue bank: acquisition and 
use of autopsy material for research on human transmis-
sible spongiform encephalopathies, Professor James Iron-
side, amended date: 9th October 2007).
hGH‑iCJD cases
22 cases of hGH-iCJD, each of which had frozen tissue 
(200 to 500  mg) available (cerebral cortex or cerebellar 
cortex), were included in this study. The patients origi-
nated from France and the UK. A diagnosis of iatrogenic 
Page 4 of 15Douet et al. acta neuropathol commun           (2021) 9:145 
CJD was made in each case according to established 
international criteria (ECDC 2021: https:// www. ecdc. 
europa. eu/ en/ infec tious- disea ses- public- health/ varia nt- 
creut zfeldt- jakob- disea se/ eu- case- defin ition). The UK 
cases are part of a larger series of UK hGH-iCJD cases 
that has been extensively characterised in terms of neu-
ropathological features,  PrPres profiles and prion protein 
amplification properties [24]. None of the patients had 
a familial history of prion disease and, in each case, the 
entire PRNP coding sequence was analysed [25, 26]. For 
each patient the age at death and the estimated incuba-
tion period (based on individual hGH treatment histo-
ries) are indicated (Table 1).
Tissue homogenate preparation
For each hGH-iCJD case, 175 ± 20 mg of frozen brain tis-
sue was homogenized in 5% glucose in distilled water in 
grinding tubes (Bio-Rad) adjusted to 10% (w/v) using a 
TeSeE™ Process 48™ homogenizer (Bio-Rad).
Transgenic mouse lines
Tg340 and tg361 mouse lines that express human PrP 
methionine at codon 129 or valine at codon 129, respec-
tively, in a prion protein gene knockout  (PrPKo) back-
ground, were generated as previously described [9, 27]. 
Both tg340 (tgMet) and tg361 (tgVal) are homozygous for 
human PRNP gene.
Mouse bioassays
Six- to ten-week-old female mice were anesthetized and 
inoculated with 2 mg of brain equivalent (20 µL of a 10% 
cerebral or cerebellar cortex homogenate) in the right 
parietal lobe using a 25-gauge disposable hypodermic 
needle.
Mice were observed daily and their neurological sta-
tus was assessed weekly by qualified veterinarians. Three 
signs of neurological dysfunction (tremor, ataxia, dif-
ficulty righting from supine position, rigidity of tail, 
kyphosis, paralysis of the lower limbs or bradykinesia,) 
were necessary to score a mouse positive for prion dis-
ease [28].
When clinically progressive TSE disease was evident, 
the animals were euthanized and their brains harvested. 
Half of the brain from those animals that had displayed 
TSE clinical signs was fixed by immersion in 10% formol 
saline and the other half was frozen at − 20  °C. Tissues 
from animals found dead were frozen (no formalin fixa-
tion). Incubation period was expressed as the mean of 
the survival (time to death) days post inoculation (dpi) of 
all the symptomatic mice scored positive for  PrPres, with 
its corresponding standard deviation.
Abnormal PrP western blot (WB) detection
PK resistant abnormal PrP extraction  (PrPres) and West-
ern blot were performed as previously described [29]. 
Immunodetection was performed using monoclonal PrP-
specific antibodie Sha31 (1  µg/ml), which recognize the 
amino acid sequence YEDRYYRE (145–152) [30].
Vacuolar lesion profiles
Hematoxylin–Eosin-stained paraffin-embedded brain tissue 
sections were used to establish standardized vacuolar lesion 
profiles in mice as previously described [3, 31]. Each lesion 
profile was based on data obtained from 4 to 6 animals.
Reference M1 and V2 CJD strains
Successive 1/10 dilutions of 10% brain homogenate (fron-
tal cortex) from a sCJD MM1 and a sCJD VV2) case were 
inoculated intra-cerebrally to tgMet (n = 6) and tgVal 
(n = 6). These data were already presented in a previous 
study [32] as cases 1 and 6, respectively. The brain of the 
last  PrPSc positive MM1 in tgMet and VV2 in tgVal mice 
(in highest dilution groups) were used to re-inoculate 
groups of tgMet (n = 12) and tgVal (n = 12). The brain 
of these tgMet and TgVal animals were pooled to con-
stitute two stocks of reference material (named  M1CJD 
and  V2CJD). The  V2CJD stock homogenate was end point 
titrated by bioassay in tgVal (inoculation of successive 
1/10 dilutions of 10% homogenates—Additional file  1: 
Table S1).
Data availability
The authors confirm that the data supporting the findings 
of this study are available within the article and its sup-
plementary material.
Results
22 hGH-iCJD cases were selected, which originated 
either from France (n = 11) or the UK (n = 11) and 
included all three possible PRNP genotypes at codon 129 
(Homozygous  Met129 or  Val129, Heterozygous  Met129/
Val129) (Table  1). In both the UK and France, the avail-
ability of hGH-iCJD cases from certain PRNP genotypes 
(such as MM in the UK or VV in France) with suitable 
biological (frozen) material was limited. Information on 
the selected 22 cases, including the estimated incubation 
period of the disease is included in Table 1.
From the frozen material available, tissue homogenates 
(10% weight volume) corresponding to either cerebral 
(frontal, parietal or temporal) cortex or cerebellar cortex 
from each hGH-iCJD case were transmitted (two itera-
tive passages) to mice homozygous for either methio-
nine (tgMet) or valine (tgVal) at codon 129 of human 
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Table 1 Transmission of tissue isolates (10% cerebral/cerebellar cortex homogenates from hGH‑iCJD cases) into mice expressing the 
human PrP (methionine, valine, at codon 129)
Isolate number Cases Brain area
Codon 129 Origin Year Age Incub period
1 MM Fr 2001 31 16 Cort
2 Fr 2006 39 21 Cort
3 Fr 2006 36 23 Cort
4 Fr 2003 33 20 Cereb
5 Fr 2004 35 21 Cort
6 UK 2011 46 29 Cort
7 UK 2012 42 32 Cort
8 MV UK 2001 30 20 Cort
9 UK 1999 37 19 Cort
10 Fr 2006 38 25 Cort
11 Fr 2008 27 24 Cereb
12 Fr 2003 35 23 Cereb
13 UK 1990 34 17 Cort
14 VV UK 1998 27 16 Cort
15 UK 1997 36 19 Cort
16 UK 1995 33 18 Cort
17 UK 1994 25 11 Cort
18 Fr 1991 11 5 Cort
19 Fr 2000 27 16 Cort
20 UK 1993 30 13 Cort
21 UK 1992 31 16 Cort




Passage 1 Passage 2 Passage3 Passage 1 Passage 2
Survival time 
(mean ± SD)
PrPres Survival time 
(mean ± SD)
PrPres Survival time 
(mean ± SD)
PrPres Survival time 
(mean ± SD)
PrPres Survival time 
(mean ± SD)
PrPres
1 585 ± 29 1 487 ± 34 1 ND 173 ± 3 2 171 ± 2 2
2 582 ± 81 1 492 ± 57 1 ND 162 ± 3 2 179 ± 7 2
3 569 ± 76 1 > 400* 163 ± 7 2 181 ± 11 2
4 593 ± 118 1 298 ± 61 1 206 ± 9 1 195 ± 13 2 165 ± 3 2
5 453 ± 137 1 204 ± 4 1 ND 180 ± 6 2 174 ± 9 2
6 246 ± 33 1 213 ± 10 1 ND 206 ± 6 2 161 ± 3 2
7 230 ± 5 1 193 ± 6 1 ND 313 ± 5 1 271 ± 5 1
8 562 ± 55 1 456 ± 6 1 ND 211 ± 12 2 173 ± 7 2
9 635 ± 66 1 503 ± 19 1 ND 172 ± 10 2 177 ± 7 2
10 525 ± 32 1 488 ± 31 1 ND 188 ± 15 2 169 ± 10 2
11 511 ± 29 1 > 400* 1 ND 164 ± 5 2 166 ± 9 2
12 566 ± 170 1 299 ± 42 1 194 ± 4 1 160 ± 10 2 163 ± 4 2
13 337 ± 66 1 212 ± 13 1 ND 193 ± 5 2 176 ± 15 2
14 626 ± 57 1 613 ± 21 1 ND 176 ± 9 2 ND 2
15 423 ± 23 1 669 ± 56 1 ND 180 ± 9 2 175 ± 5 2
16 665 ± 15 1 484 ± 30 1 ND 165 ± 5 2 175 ± 14 2
17 628 ± 83 1 568 ± 82 1 ND 198 ± 7 2 169 ± 7 2
18 565 ± 19 1 > 400* 1 165 ± 5 2 180 ± 10 2
19 759 ± 64 1 > 400* 1 171 ± 7 2 177 ± 8 2
20 612 ± 122 1 312 ± 49 1 202 ± 4 1 178 ± 7 2 180 ± 7 2
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PrP (Table 1). These two tgHu PrP mouse lines have been 
shown to express approximately fourfold more  PrPC in 
their brain than human brain tissue [9].
In parallel, French (n = 7) and UK (n = 4) cases of sCJD, 
classified as MM1, MV1, MV2 and VV2, were trans-
mitted to tgMet and TgVal. (Table  2). Data from these 
sCJD transmissions have been previously reported in a 
recent study that aimed to type the prion strains in the 
brain of MM/MV1 and VV/MV2 sCJD affected patients 
[11]. Based on the transmission properties of incuba-
tion period, lesion profile and biological cloning of prion 
component present in different brain isolates, this study 
allowed the identification of two sCJD strains, named 
as  M1CJD and  V2CJD, that could be present as either 
pure components or as a mixture in the sCJD isolates 
(Table 2).
In the French and UK hGH-iCJD isolates, three distinct 
transmission patterns were observed in mice inoculated 
with the panel of tissue homogenates.
The first and most frequent transmission pattern 
(n = 13 cases), was observed in French MM (n = 3, cases 
1–3), MV (n = 2, cases 10,11) and VV (n = 2, cases 18,19); 
and UK MV (n = 2, cases 8,9), VV (n = 4, cases 14–17) 
hGH-iCJD patients. It was characterized by a short incu-
bation period in tgVal (~ 160 to 180 dpi) and a long incu-
bation period in tgMet (~ 400 to 700 dpi) (Table 1, Fig. 1). 
All tgMet mice accumulated a type 1  PrPres in their brain, 
while type 2  PrPres was observed in the brain collected 
from tgVal mice (Table 1, Fig. 2).
This pattern was very similar to that observed in tgMet 
and tgVal inoculated with the  V2CJD strain (Table  3, 
Fig. 1) which was observed in the brain of some French 
and UK MV2 and VV2 sCJD-affected patients (cases 
30–32) (Table 2). The vacuolar lesion profile in the brain 
of the mice (after second passage) confirmed the propa-
gation of the  V2CJD prion strain in both the tgMet and 
tgVal that had been inoculated with these 13 hGH-iCJD 
cases (Fig. 3).
The second transmission pattern observed was 
observed in one MM UK hGH-iCJD case (case 7). It 
was characterized by a short incubation period in tgMet 
(~ 200 dpi), and a longer one in tgVal (~ 300 dpi) (Table 1, 
Fig. 1). Irrespective of the inoculated mouse line, a type 
1  PrPres was observed in the brain of the inoculated ani-
mals (Table 1, Fig. 1). These features were similar to those 
associated with the transmission of the  M1CJD strain 
(Table  3) which could be observed in French and UK 
MM1 and in a part of the MV1 sCJD affected patients 
(cases 23–26) (Table 2). The vacuolar lesion profile in the 
brain of the inoculated mice (after second passage) con-
firmed the propagation of  M1CJD prion strain in tgMet 
and tgVal inoculated with hGH-iCJD case 7.
In another case (case 22, French origin, VV genotype), 
available transmission results and lesion profiles in tgMet 
and tgVal, were also compatible with the presence of 
 M1CJD strain. However, incomplete second passage of this 
isolate in tgVal at the time of writing precluded drawing 
a definitive conclusion on the nature of the prion strain.
A third transmission profile was identified in French 
MM (n = 2, cases 4, 5) and MV (n = 1, case 12) cases as 
well as in UK MM (n = 1, case 6), MV (n = 1, case 13) and 
VV (n = 2, cases 20, 21) patients.
This transmission pattern was characterized on second 
passage by a short incubation period in tgMet (~ 200–300 
dpi), and a short incubation period in tgVal (about 160–
200 dpi) (Table 1, Fig. 1). A type 1  PrPres accumulated in 
the brain of tgMet while type 2  PrPres was observed in 
tgVal mice (Fig. 2). In these isolates, the vacuolar lesion 
Transgenic mice that express the  Met129 (tgMet),  Val129 (tgVal) human PrP were inoculated intra-cerebrally (20µL per mouse) with human growth hormone (hGH) 
iatrogenic Creutzfeldt–Jakob brain tissue homogenates (frontal, temporal or parietal cortex: (cort) or cerebrellar cortex: (cereb)) from patients originating (orig.) 
from France (Fr), or the United Kingdom (UK). The hGH-iCJD patients displayed different PRNP genotypes at codon 129 (MM: homozygous  Met129, VV: homozygous 
 Val129, MV: heterozygous Met/Val129). For each patient, the country of origin, the year of death and age in years at death are indicated. The estimated duration of the 
incubation period in years (based on the hGH treatment history) is also indicated. After the first and second passages, brain tissue from the clinically affected mice 
were pooled and used for a next passage in the same line. The  PrPres WB isoforms (type 1 or type 2) identified in mouse brains are reported for each two passages. 
Survival times are shown as mean ± standard deviation (SD). 100% attack rate transmission were observed in all cases
ND not done
*Transmission still ongoing with no dead animals observed at the reported date





Passage 1 Passage 2 Passage3 Passage 1 Passage 2
Survival time 
(mean ± SD)
PrPres Survival time 
(mean ± SD)
PrPres Survival time 
(mean ± SD)
PrPres Survival time 
(mean ± SD)
PrPres Survival time 
(mean ± SD)
PrPres
21 446 ± 165 1 210 ± 12 1 ND 194 ± 7 2 170 ± 3 2
22 362 ± 48 1 229 ± 8 1 ND 439** 1 ND
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Fig. 1 Survival times of human PrP‑expressing mice (tgHu) inoculated with growth hormone CJD cases originating from France and UK. Transgenic 
mice that express the  Met129 (tgMet),  Val129 (tgVal) human PrP were inoculated intra‑cerebrally (6 mice, 20µL per mouse) with a 10% brain 
homogenate from hGH‑iCJD cases of French and UK origin. Two iterative passages were performed in each mouse line (Table 1). For each passage, 
results are presented according to the country of origin (Fr and UK) and the PRNP codon 129 genotype of patients (homozygous Met129: MM—
heterozygous Met129/Val129: MV—homozygous Val129: VV). Survival time (mean ± SD in days post inoculation) in tg Met (○) and tg Val (∆). White/
black symbols correspond to a type 1/type 2  PrPres (as assessed by Western blot) in the brain of the mice respectively. Survival times in tgMet and 
TgVal associated with  M1CJD and  V2CJD cloned strains as well as an artificial mixture of  V2CJD +  M1CJD  (10–4 diluted) are included as reference (see 
Table 2)
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profiles in the TgMet matched with the profiles observed 
in mice inoculated with  M1CJD strain while in the tgVal 
mice it corresponded to the  V2CJD strain (Fig.  3). Strik-
ingly, the transmission of artificial mixtures containing 
 V2CJD cloned strain and a low dilution  (10–3 to  10–4) of 
the  M1CJD cloned strain in tgMet and TgVal mice resulted 
in similar transmission patterns (Table 3, Fig. 3).
Discussion
Representativeness of the panel of hGH‑iCJD cases
hGH-iCJD cases are considered to be the consequence of 
childhood treatment with human growth hormone, pre-
pared using pituitary glands collected from donors that 
were either affected with or at a late stage of incubation 
of sCJD. France (n = 122) and the UK (n = 81) account 
for the largest numbers of hGH-iCJD patients identi-
fied worldwide. The epidemiological profile of the hGH-
iCJD cases in these countries differs in the distribution 
of PRNP genotypes at codon 129 and in the mean incu-
bation period in each genotype group. These differences 
between the UK and France have been proposed to have 
resulted from contamination with different prion strains 
[16, 23, 24].
Bioassays in reporter animal models, followed by the 
phenotyping of the propagated prions (vacuolar lesion 
profile in the brain and incubation period) remains 
the gold standard approach for the characterization 
of prion strains. Over the last decade, transgenic mice 
that express different human PrP variants at codon 
129 (tgHu) have been shown to be valuable models in 
which to discriminate between different human prion 
agents and have provided valuable insights in the diver-
sity of the prion strains responsible for sCJD [8–13]. 
These mouse models have allowed the identification of 
five different prion strains associated with sCJD among 
which two, named  M1CJD and  V2CJD, are thought 
responsible for the most frequent clinico-pathological 
forms of sCJD (observed in MM/MV1 and VV/MV2 
patients, respectively) [8–11]. These same animal mod-
els also demonstrated that in around 30% of the MV1, 
Fig. 2 PrPres western blot profiles in the brains of human PrP‑expressing mice (TgHu) inoculated with human growth hormone iatrogenic CJD 
(hGH‑iCJD) cases. Transgenic mice that express the  Met129 (tgMet) or  Val129 (tgVal) human PrP were inoculated intra‑cerebrally (6 mice, 20µL per 
mouse) with a 10% brain homogenate from hGH‑ iCJD cases of French and UK origin. Two iterative passages were performed in each line (Table 1). 
After each passage and in each mouse line the isoform (type 1/type 2) of the  PrPres was determined in mice brain by SDS‑PAGE and WB with the 
anti‑PrP monoclonal antibody Sha31 (epitope YEDRYYRE). A  PrPres type 1 isoform (MM1 sCJD isolate) and type 2 isoform (VV2 sCJD isolate) were 
included as controls on each gel. The WB results obtain in each line are reported in Table 1
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MV2 and VV2 sCJD patients both  M1CJD and  V2CJD 
prions were present as a mixture [11].
Transmission of the 11 French and 11 UK hGH-iCJD 
cases in mice expressing valine 129 (tgVal) and methio-
nine 129 (tgMet) human PrP variants in this study, rep-
resents an unprecedented effort to document the nature 
of the prion strains responsible for this iatrogenic form 
of the disease. Our study was primarily designed to test 
the hypothesis that different prion agents were respon-
sible for the hGH-iCJD outbreaks in France and in the 
UK. While the design of the experiments was fit for 
this purpose, the materials (cost and duration of bioas-
say, availability of material from patients) and ethical 
considerations limited the number of hGH-iCJD cases 
that could undergo strain typing by bioassay.
Prion strains in the UK and French hGH‑iCJD cases
The prion strains that were identified in brain isolates 
prepared from French and UK hGH-iCJD cases follow-
ing bioassay in tgHu mice models correspond to prion 
strains that were previously identified in sCJD patients in 
France and in the UK using the same mouse models [11].
In contradiction to the initial hypothesis, the prion 
strains that were identified in the UK and the French GH-
cases were not radically different.
Fig. 3 Vacuolar lesion profiles in the brain of human PrP‑expressing mice (tgHu) inoculated with human growth hormone iatrogenic CJD cases 
originating from France and UK. French (Fr) and UK hGH‑iCJD isolates were inoculated in transgenic mice that express  Met129 (tgMet) or  Val129 
(tgVal) human PrP (intra‑cerebral route, 6 mice, 20µL per mouse). After two iterative passages standardized vacuolar lesion profiles were established 
in the brains of the mice. Lesion profiles corresponding to  M1CJD (○) and  V2CJD (●) strains are presented for comparison. Results are presented 
according to the origin (Fr and UK) and the genotype of patients (homozygous Met129: MM—heterozygous Met129/Val129: MV—homozygous 
Val129: VV°). Fr MM cases: case 1 (∇), case 2 (∆), case 5 (○). UK MM: case 6 (○), case 7 (∇). Fr MV: case 10 (○), case 12 (∆). UK MV: case 11: case 9 (∇), 
cases 9 (○), case 13(∆). Fr VV cases: case 18 (∆), case 19 (∇), case 22 (○). UK VV cases: case 14 (○), case 15 (∆), case 22 (∇). For the Fr VV cases 18 and 
19, second passage in tgMet were not available at the moment of writing (see Table1)
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In the vast majority of the UK (10 out 11) and French 
(10 out 11) cases, the  V2CJD strain or a mixture of 
 M1CJD +  V2CJD strains were identified by the strain typing 
bioassays.
A pure  V2CJD strain was observed in all three PRNP 
genotypes in French hGH-iCJD patients and in two 
PRNP genotypes (MV and VV) in the UK patients. In 
both countries,  M1CJD +  V2CJD strain mixtures were 
identified in the three different PRNP genotypes. A pure 
 M1CJD strain was identified in a single UK patient (case 7, 
MM genotype) and suspected in a French patient (case 
22, VV genotype -definitive transmission results not yet 
available).
These data strongly support the contention that the 
difference of epidemiological profile observed between 
the UK and the French hGH-iCJD outbreaks cannot be 
attributed to the transmission of different prion strains.
V2 dominant presence is concordant with previous 
investigations in the UK
In the UK, several studies have addressed the question sur-
rounding the prion strains responsible for hGH-iCJD, by 
the characterisation of the neuropathology features and/or 
the  PrPres biochemical properties in the brain of hGH-iCJD 
affected individuals, including those cases investigated by 
bioassay in this study [22, 24, 33]. So far, no comprehen-
sive description of the neuropathological and biochemical 
 PrPres properties in the French hGH-iCJD cohort is avail-
able in the literature.
In a large number of VV and MV UK hGH-iCJD patients, 
neuropathological features that are considered characteris-
tic of VV2 sCJD cases (including plaque-like deposits) were 
identified. Along with the biochemical profile of the UK VV 
and MV hGH-iCJD cases, this leads to the proposal that 
pituitary glands collected from VV2 sCJD case(s) might 
have played a preponderant role in the UK hGH-iCJD out-
break [22, 24].
The results of this study supports this hypothesis, with 
the unambiguous identification of the  V2CJD strain that was 
obtained by bioassay of brain homogenate from 6 out of the 
9 VV and MV UK hGH-iCJD cases.
Similarly, the identification of MM1-like sCJD neuro-
pathological, biochemical and protein misfolding cyclical 
amplification (PMCA) features reported in case hGH-iCJD 
21 in the earlier study by Ritchie et  al. concurs with the 
pure  M1CJD strain phenotype we observed in tgHu mice 
inoculated with cerebral cortex homogenate from the same 
patient (case 7 in this study). The other UK PRNP codon 
129 MM hGH-iCJD case reported by Ritchie et  al. (case 
hGH-iCJD 20) had atypical neuropathological and bio-
chemical features along with PMCA features that suggested 
the influence of a V2 strain. This case was also included 
in the present study as case 6, which had transmission 
characteristics different from case 7, suggesting a mixed 
 M1CJD/V2 CJD strain effect. The transmission findings in 
cases 6 and 7 therefore provide a direct in vivo correlation 
that confirms the in vitro findings of Ritchie et al. [24].
Coexistence of several strains in French and UK hGH‑iCJD 
cohorts
The identification of mixed  M1CJD and  V2CJD strains in 
both the UK and the French hGH-iCJD cases raises the 
question of the origin of this strain diversity.
The pooling of pituitary glands during hGH production 
from several individuals affected with different strains 
of sCJD may be one explanation for this phenomenon. 
However, since the co-existence of  M1CJD and  V2CJD 
strains have been reported in up to 35% of sCJD cases, 
the use of pituitary gland from a single donor may also 
explain the presence of the two strains [7, 11, 34].
In France, 12 batches of extracted hGH, all produced 
between January 1982 and December 1985, were identi-
fied as the potential source of infection. According to 
available data, a batch was in average produced from 
1000 to 1500 pituitary glands, meaning that tissue from 
up to 18 000 individuals may have contributed to the at-
risk batches [18].
In the UK it is estimated that around 200,000 pituitary 
glands were used to produce the hGH extracts that were 
used to treat patients that later developed hGH-iCJD 
[17].
The sCJD prevalence in industrialized countries is esti-
mated to be approximatively 1.5 cases per million people 
and per year [35]. In people aged over 50, sCJD frequency 
significantly increases to reach 5.5 to 7.5 case per mil-
lion people per year in individuals aged between 65 and 
79 [36, 37]. However, in France and in the UK (each with 
a similar population size), between 600,000 and 700,000 
deaths are recorded each year, with 80–130 sCJD cases 
diagnosed annually. Based on these figures, the possibil-
ity exists that more than one infectious pituitary gland 
could have entered in the production of the at-risk hGH 
batches in both France and the UK.
Epidemiological profiles in both countries
Assuming that the same prion strains are responsible 
for the UK and French hGH-iCJD cases, the question 
remains of  how the epidemiological differences occur-
ring between the two hGH-iCJD case cohorts may  be 
explained.
The frequency of Met/Met129, Met/Val129 and Val/
Val129 individuals in the general population and in their 
distribution in sCJD cases are similar in France and in the 
UK [16]. The hGH therapeutic scheme in both countries, 
including the route of administration (in general intra-
muscular) and the average age of administration were 
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also similar, making these parameters unlikely explana-
tions for the observed epidemiological differences [17–
19, 23].
In experimental TSE models, longer and more wide-
spread incubation periods are classically observed when 
animals are exposed to decreasing doses of infectiv-
ity [38]. The average incubation duration for hGH-iCJD 
patients from each PRNP codon 129 genotype were sig-
nificantly longer in the UK patients (VV: 14.3 years–MV: 
23.4 years–MM: 30.8 years) when compared with French 
patients (VV: 9 years–MV: 17.6 years–MM: 12 years) [16, 
22]. These elements support the hypothesis that French 
hGH-iCJD affected patients could have been exposed to 
higher infectious doses than the UK patients.
Although the relevance of findings in experimental 
TSE models to the physiopathology of CJD in humans is 
uncertain, they could provide some valuable insights on 
the relative abilities of sCJD strains to propagate in hosts 
expressing different human PrP variants.
The end point titrations of  V2CJD and  M1CJD in tgMet 
and tgVal indicated that the  M1CJD strain displays a 
1000-fold lower capacity to propagate in  Val129 than in 
 Met129 PrP-expressing host (Additional file 1: Table S1). 
Conversely, one infectious dose  (ID50) of  V2CJD strain (as 
measured by the intracerebral route in tgVal) transmits 
with shorter incubation period in tgVal than  107.2  ID50 
 M1CJD strain (as measured by the intracerebral route in 
tgMet) [11, 32].
When tgHu mice are co-infected with  M1CJD and V2 
CJD prions, the nature of the strain(s) that propagate in 
the brain of the recipients depends on the PRNP geno-
type at codon 129 and to the specific amount of  M1CJD 
and  V2CJD infectivity in the inoculum, resulting in the 
presence of either  M1CJD +  V2CJD strain mixture or of 
a pure  M1CJD or  V2CJD strain in the infected host brain 
(Table 3) [11]. Based on these elements, a scenario where 
 M1CJD and  V2CJD would display different abilities to prop-
agate in an individual according to his genotype at codon 
129 and the infectious titre of each strain seems plausible. 
At low infectious doses, as seems possible in the UK hGH 
situation, the  V2CJD strain would dominate, mostly in VV 
individuals.
The isolation of a sub-dominant  M1CJD strain in 
homozygous (cases 4 and 5) and heterozygous (case 12) 
 Met129 patients indicates that French hGH-iCJD patients 
were exposed to this prion strain. The transmission of the 
 M1CJD and  V2CJD strain in tgMet mice support the view 
that the  M1CJD strain, even if present at very low level in 
the extractive hGH, should propagate as the dominant 
strain in the homozygous  Met129 patients. The identi-
fication of the  V2CJD strain as dominant prion strain in 
the brain of the homozygous  Met129 French hGH-iCJD 
patients is therefore surprising.
These observations could be explained by the effects of 
a peripheral (non-CNS) route of transmission that would 
differentially impact on the relative efficiency of  M1CJD 
and  V2CJD transmission by the intramuscular route of 
exposure in hGH recipients, resulting in a slow or inef-
ficient transmission of the  M1CJD strain.
In a given host, the inoculation by a peripheral route 
of two prion strains can result in radically different trans-
mission profile, depending on their capacity to repli-
cate early in the lymphoid tissues before neuroinvasion. 
The inoculation of  the HY prion strain in hamsters by 
the intracerebral, the intraperitoneal or the oral route 
resulted in all three instances in a highly efficient trans-
mission (100% attack rate) of the disease. The inoculation 
of the DY prion strain in hamsters by the intra cerebral 
route also resulted in a prion disease. In sharp contrast, 
the inoculation of a high infectious dose of DY prions in 
hamsters by the intraperitoneal or the oral route failed 
to transmit the disease [39, 40]. HY but not DY are able 
to replicate at detectable levels in the lymphoid tis-
sue. Interestingly,  V2CJD strains appeared to replicate at 
higher levels than  M1CJD strain in the lymphoid tissue of 
tgMet mice [10].
Further investigations will be necessary to confirm the 
influence of the intramuscular route of infection in mod-
ulating  M1CJD and  V2CJD strain transmission efficiencies. 
Beyond this, the characterization of the  PrPres and meas-
urement of the infectivity levels in the pituitary glands 
of sCJD patients and the impact of hGH extraction pro-
cesses on  M1CJD and  V2CJD strains from the pituitary 
glands (removal of infectivity) would be very helpful for 
appreciating the potential exposure conditions to prions 
in hGH-treated patients. Ultimately, the direct character-
isation of prion infectivity levels and strains in the French 
and UK hGH-batches that appear to have resulted in the 
transmission of hGH-iCJD would be very informative.
Although numerous elements are still lacking to fully 
understand the difference existing between the French 
and UK hGH-iCJD case cohorts, the results that we 
report in this study indicate that the nature of the prion 
strains involved are not fundamental to the observed dif-
ferences in epidemiological profiles.
Finally, the number of hGH-iCJD cases that we investi-
gated (n = 22) should be considered as relatively limited 
when compared to the total number of hGH-iCJD cases 
identified in France (n = 122) or the UK (n = 81). There-
fore, we cannot be certain that the panel of hGH-iCJD 
cases that we investigated necessarily provides a full pic-
ture of the prion strain diversity in the French and the 
UK hGH-iCJD cohorts.
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